viewLexaria Bioscience Corp.

Full interview: Lexaria BioScience signs massive licensing deal with Cannadips CBD

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California.

Bunka telling Proactive this is a massive deal for the company that will see products in roughly 5000 stores across the U.S. and will have more retail locations selling Lexaria product that all the legal cannabis dispensaries across North America combined. 

Quick facts: Lexaria Bioscience Corp.

Price: 0.52 CAD

Market: CSE
Market Cap: $46.59 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...



Lexaria Bio Science and partner Altria complete Phase One of the development...

Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures. Bunka says everything went as planned and...

2 weeks, 6 days ago

2 min read